Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators, John W Eikelboom, Graeme J Hankey, Jim Thom, Deepak L Bhatt, P Gabriel Steg, Gilles Montalescot, S Claiborne Johnston, Steven R Steinhubl, Koon-Hou Mak, J Donald Easton, Christian Hamm, Tingfei Hu, Keith A A Fox, Eric J Topol

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydro thromboxane B(2) concentrations, has been associated with an increased risk of cardiovascular events. We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B(2) concentrations that could thereby reduce cardiovascular risk.
Original languageEnglish
Pages (from-to)1705-12
Number of pages8
JournalCirculation
Volume118
Issue number17
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Dive into the research topics of 'Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk'. Together they form a unique fingerprint.

Cite this